Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells

Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leuk...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Maiko Matsushita
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	chronic myelogenous leukemia leukemic stem cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d155489c7fbd45afb4e1e6b21cb70aad
record_format	dspace
spelling	oai:doaj.org-article:d155489c7fbd45afb4e1e6b21cb70aad2021-11-11T15:31:44ZNovel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells10.3390/cancers132154352072-6694https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad2021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5435https://doaj.org/toc/2072-6694Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.Maiko MatsushitaMDPI AGarticlechronic myelogenous leukemialeukemic stem cellsimmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5435, p 5435 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic myelogenous leukemia leukemic stem cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chronic myelogenous leukemia leukemic stem cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maiko Matsushita Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
description	Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.
format	article
author	Maiko Matsushita
author_facet	Maiko Matsushita
author_sort	Maiko Matsushita
title	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
title_short	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
title_full	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
title_fullStr	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
title_full_unstemmed	Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
title_sort	novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad
work_keys_str_mv	AT maikomatsushita noveltreatmentstrategiesutilizingimmunereactionsagainstchronicmyelogenousleukemiastemcells
_version_	1718435271676002304

Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells

Ejemplares similares